Patient-specific radiation dosimetry of99mTc-HYNIC-Tyr 3-octreotide in neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1474-1481

  Grimes, Joshua ^a   Celler, Anna ^a   Birkenfeld, Bozena ^b   Shcherbinin, Sergey ^a   Listewnik, Maria H ^b   Piwowarska Bilska, Hanna ^b   Mikołajczak, Renata ^c   Zorga, Piotr ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c IAE POLATOM Radioisotope Centre   (Poland)

Author keywords

99mTc HYNIC Tyr3 octreotide; Neuroendocrine tumors; Patient specific dosimetry; Somatostatin receptor imaging; SPECT CT

Indexed keywords

HYDRAZINONICOTINAMIDE OCTREOTIDE[3 TYROSINE] TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; DOSIMETRY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG UPTAKE; FEASIBILITY STUDY; FEMALE; HUMAN; KIDNEY; LIVER; MALE; NEUROENDOCRINE TUMOR; PHANTOM; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPLEEN; WHOLE BODY IMAGING;

ADULT; AGED; ALGORITHMS; FEMALE; HALF-LIFE; HUMANS; IMAGING, THREE-DIMENSIONAL; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; PHANTOMS, IMAGING; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 80052643599     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.088203     Document Type: Article

References (22)

1. Reubi J, Waser B, Schaer J, Laissue J. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-846. (Pubitemid 32662546)
2. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med Mol Imaging. 1993;20:716-731.
3. 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000;27:1318-1325.
4. 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication. Eur J Nucl Med Mol Imaging. 2003;30:1402-1406.
5. 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1635-1645.
6. 111In-DTPA- octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003;44:708-716.
7. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl):172S-178S.
8. 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
9. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850-856.
10. 3- octreotide prepared from lyophilized kits. Appl Radiat Isot. 2006;64:792-797.
11. Koral KF, Zasadny KR, Kessler ML, et al. CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med. 1994;35:1714-1720. (Pubitemid 24307770)
12. Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247-250. (Pubitemid 37485998)
13. Siegel JA, Thomas SR, Stubbs JB, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(suppl):37S-61S. (Pubitemid 29077103)
14. Shcherbinin S, Celler A, Belhocine T, Vanderwerf R, Driedger A. Accuracy of quantitative reconstructions in SPECT/CT imaging. Phys Med Biol. 2008;53:4595-4604.
15. Wells RG, Celler A, Harrop R. Analytical calculation of photon distributions in SPECT projections. IEEE Trans Nucl Sci. 1998;45:3202-3214. (Pubitemid 128744675)
16. Vandervoort E, Celler A, Wells G, Blinder S, Dixon K, Pang Y. Implementation of an analytically based scatter correction in SPECT reconstructions. IEEE Trans Nucl Sci. 2005;52:645-653. (Pubitemid 41172555)
17. Erdi YE, Wessels BW, Loew MH, Erdi AK. Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Cancer Res. 1995;55(23 suppl):5823s-5826s.
18. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry - standardization of nomenclature. J Nucl Med. 2009;50:477-484.
19. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027. (Pubitemid 43733519)
20. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging. 2009;36:182-193.
21. Radiation dose to patients from radiopharmaceuticals (addendum to ICRP publication 53): ICRP publication 80. Ann ICRP. 1998;28.
22. He B, Wahl RL, Du Y, et al. Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning: Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008;27:521-530. (Pubitemid 351479144)